AptaBio Therapeutics Inc. (293780.KQ)
KRW 6500.0
(-3.56%)
KRW 6500.0
(-3.56%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 323.86 Million KRW | 569.8% |
| 2022 | 48.35 Million KRW | -78.38% |
| 2021 | 223.67 Million KRW | -34.41% |
| 2020 | 341.04 Million KRW | -66.52% |
| 2019 | 1.01 Billion KRW | -29.95% |
| 2018 | 1.45 Billion KRW | 384.6% |
| 2017 | 300.06 Million KRW | -49.73% |
| 2016 | 596.9 Million KRW | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 1.12 Billion KRW | 75.81% |
| 2024 Q1 | 637.23 Million KRW | 120.34% |
| 2023 Q2 | 6.78 Million KRW | -65.19% |
| 2023 Q3 | 8.38 Million KRW | 23.62% |
| 2023 Q4 | 289.2 Million KRW | 3348.52% |
| 2023 Q1 | 19.48 Million KRW | 8.95% |
| 2023 FY | 323.86 Million KRW | 569.8% |
| 2022 FY | 48.35 Million KRW | -78.38% |
| 2022 Q4 | 17.88 Million KRW | 20.55% |
| 2022 Q3 | 14.83 Million KRW | -5.04% |
| 2022 Q2 | 15.62 Million KRW | 55.27% |
| 2022 Q1 | 10.06 Million KRW | -19.21% |
| 2021 FY | 223.67 Million KRW | -34.41% |
| 2021 Q3 | 18.94 Million KRW | -77.93% |
| 2021 Q2 | 85.83 Million KRW | -19.35% |
| 2021 Q1 | 106.43 Million KRW | 443.14% |
| 2021 Q4 | 12.45 Million KRW | -34.25% |
| 2020 Q1 | 47.99 Million KRW | -79.87% |
| 2020 Q4 | 19.59 Million KRW | -65.45% |
| 2020 FY | 341.04 Million KRW | -66.52% |
| 2020 Q3 | 56.72 Million KRW | -73.83% |
| 2020 Q2 | 216.72 Million KRW | 351.57% |
| 2019 Q4 | 238.47 Million KRW | -5.28% |
| 2019 FY | 1.01 Billion KRW | -29.95% |
| 2019 Q3 | 251.77 Million KRW | -49.2% |
| 2019 Q2 | 495.6 Million KRW | 0.0% |
| 2018 Q4 | 47.28 Million KRW | -95.59% |
| 2018 Q3 | 1.07 Billion KRW | 315.85% |
| 2018 Q2 | 257.83 Million KRW | 0.0% |
| 2018 FY | 1.45 Billion KRW | 384.6% |
| 2017 FY | 300.06 Million KRW | -49.73% |
| 2016 FY | 596.9 Million KRW | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| HLB Pharmaceutical Co., Ltd | 135.95 Billion KRW | 99.762% |
| CMG Pharmaceutical Co., Ltd. | 93.9 Billion KRW | 99.655% |
| Celltrion Pharm, Inc. | 388.79 Billion KRW | 99.917% |
| Huons Global Co., Ltd. | 758.37 Billion KRW | 99.957% |
| DongKook Pharmaceutical Co., Ltd. | 730.99 Billion KRW | 99.956% |
| Enzychem Lifesciences Corporation | 76.03 Billion KRW | 99.574% |
| Humedix Co., Ltd. | 152.27 Billion KRW | 99.787% |
| Boditech Med Inc. | 134.21 Billion KRW | 99.759% |
| EuBiologics Co., Ltd. | 69.36 Billion KRW | 99.533% |
| FutureChem Co.,Ltd | 13.96 Billion KRW | 97.681% |
| Huons Co., Ltd. | 552 Billion KRW | 99.941% |
| BNC Korea Co., Ltd. | 80.99 Billion KRW | 99.6% |